Financial News
Articles published by Pfizer Inc.
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
July 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
June 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
June 23, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2023 Dividend
June 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
June 20, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 06, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
May 30, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
May 25, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Prices $31,000,000,000 Debt Offering
May 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Announces Proposed Notes Offering
May 15, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Reports First-Quarter 2023 Results
May 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
April 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares Second-Quarter 2023 Dividend
April 26, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
April 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
March 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
March 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.